Abstract
In a pilot study a carboplatinum, 250 mg/m2 i.V., and 4-epidoxirubicin, 90 mg/m2 i.v. or mitoxantrone, 10 mg/m2 i.v., combination chemotherapy regimen was studied in a group of breast cancer patients with high-risk metastatic disease. All 11 patients had liver and/or lung metastases. Of the 11 patients, 9 had progressive disease and in 2 patients the disease had stabilised. The toxicity of both anthracycline-containing regimes was similar. Subjective toxicity was mild, but hematological toxicity was inacceptable. The tested carboplatinum-anthracycline combination regimes given in the administered doses are not useful in the treatment of metastatic breast cancer, mainly because of toxicity.
Key words: Metastatic breast cancer, Carboplatinum, Mitoxantrone, 4-Epidoxirubicin
References
- Kolaric K, Roth A, Vukas D, Cervek J (1984) CAP versus CMFVP combination chemotherapy in untreated metastatic breast cancer. Cancer Chemother Pharmacol 13:142–144 [DOI] [PubMed] [Google Scholar]
- Creagan ET, Green SJ, Ahmann DL, Ingle JN, Edmonson JH, Marschke RF Jr. (1984) A phase III clinical trial comparing the combination cyclophosphamide/Adriamycin/cisplatin with cyclophosphamide/5-fluorouracil/prednisone in patients with advanced breast cancer. J Clin Oncol 11, 1260–1265 [DOI] [PubMed] [Google Scholar]